The heart is a vital organ that is unfortunately the center of many debilitating conditions. Heart disease, which is the umbrella term for many different kinds of heart conditions, is a leading cause of deaths worldwide. Our Laboratory studies treatments for genetic heart disease, heart failure, and atherosclerosis. We approach genetic heart disease via gene therapy, and heart failure and atherosclerosis via drug delivery.

Citation:

• Moore, Ben. “Am I at Risk for Cardiovascular Disease?” University Diagnostic Medical Imaging, February 24, 2021. https://www.udmi.net/cardiovascular-disease-risk/.
• Switala L;Di L;Colantonio S;Lakshman B;Caceres TW;Reading JJ;Garcia-Buntley SS;Maiseyeu A; “The Development and Characterization of Two Monoclonal Antibodies against the Conjugates and Derivatives of the Immunometabolite Itaconate.”
• Hong NE;Chaplin A;Di L;Ravodina A;Bevan GH;Gao H;Asase C;Gangwar RS;Cameron MJ;Mignery M;Cherepanova O;Finn AV;Nayak L;Pieper AA;Maiseyeu A; “Nanoparticle-Based Itaconate Treatment Recapitulates Low-Cholesterol/Low-Fat Diet-Induced Atherosclerotic Plaque Resolution.”
• Syed R;Rengasamy P;Rajagopalan S;Deiuliis JA;Maiseyeu A; “MicroRNA 223 Enhances ABCA1 Protein Stability and Supports Efflux in Cholesterol-Burdened Macrophages.” Cell biochemistry and biophysics.
• Edwards-Glenn JM;Fontes MT;Waigi EW;Costa TJ;Maiseyeu A;Webb RC;McCarthy CG;Wenceslau CF; “Specialized Pro-Resolving Mediator Improves Vascular Relaxation via Formyl Peptide Receptor-2.” American journal of hypertension.
• Nayak L;Sweet DR;Thomas A;Lapping SD;Kalikasingh K;Madera A;Vinayachandran V;Padmanabhan R;Vasudevan NT;Myers JT;Huang AY;Schmaier A;Mackman N;Liao X;Maiseyeu A;Jain MK; “A Targetable Pathway in Neutrophils Mitigates Both Arterial and Venous Thrombosis.” Science translational medicine.
• Maiseyeu A;Di L;Ravodina A;Barajas-Espinosa A;Sakamoto A;Chaplin A;Zhong J;Gao H;Mignery M;Narula N;Finn AV;Rajagopalan S; “Plaque-Targeted, Proteolysis-Resistant, Activatable and MRI-Visible Nano-GLP-1 Receptor Agonist Targets Smooth Muscle Cell Differentiation in Atherosclerosis.” Theranostics.
• Ravodina AM;Badgeley MA;Rajagopalan S;Fedyukina DV;Maiseyeu A; “Facile Cholesterol Loading with a New Probe Ezflux Allows for Streamlined Cholesterol Efflux Assays.” ACS omega.
• Yasmeen R;Shen Q;Lee A;Leung JH;Kowdley D;DiSilvestro DJ;Xu L;Yang K;Maiseyeu A;Bal NC;Periasamy M;Fadda P;Ziouzenkova O; “Epiregulin Induces Leptin Secretion and Energy Expenditure in High-Fat Diet-Fed Mice.” The Journal of endocrinology.
• Yao Z;Mates JM;Cheplowitz AM;Hammer LP;Maiseyeu A;Phillips GS;Wewers MD;Rajaram MV;Robinson JM;Anderson CL;Ganesan LP; “Blood-Borne Lipopolysaccharide Is Rapidly Eliminated by Liver Sinusoidal Endothelial Cells via High-Density Lipoprotein.” Journal of immunology
• Ganesan LP;Mates JM;Cheplowitz AM;Avila CL;Zimmerer JM;Yao Z;Maiseyeu A;Rajaram MV;Robinson JM;Anderson CL; “Scavenger Receptor B1, the HDL Receptor, Is Expressed Abundantly in Liver Sinusoidal Endothelial Cells.” Scientific reports.
• S;, Zhong J;Maiseyeu A;Rajagopalan. “Lipoprotein Effects of Incretin Analogs and Dipeptidyl Peptidase 4 Inhibitors.” Clinical lipidology.
• S;, Zhong J;Maiseyeu A;Davis SN;Rajagopalan. “DPP4 in Cardiometabolic Disease: Recent Insights from the Laboratory and Clinical Trials of DPP4 Inhibition.” Circulation research.